Rothschild Redburn analyst Simon Baker downgraded Moderna (NASDAQ: MRNA) from Neutral to Sell with a price target of $81.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades